Aytu BioPharma, Inc.

AYTU

NASDAQ · Specialty & Generic Pharma

$2.31

At close - Sep 24, 4:00 PM EDT - USD

Market Cap$19M

P/E-1.1x

52W High$3.07

Volume69.98K

VCP Research Verdict2026Q3

Persistent Revenue Contraction Challenges Operational Viability

Aytu BioPharma faces a challenging outlook as its core ADHD and specialty portfolio struggles to maintain market share, evidenced by a revenue decline to $12.4M in 2026Q3 from $18.7M in 2024Q2. The company's inability to achieve operating scale, highlighted by...

GrowthContracting

ProfitabilityNegative

ValuationReview

TechnicalsWeak

Explore valuation models

MARKET ACTION

AYTU price & volume

Price trend, volume and key moving averages

Launch Terminal

Loading chart...

Market performance

Price History →

Trailing total returns as of 9/25/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return

AYTU-16.61%

S&P 500 (^GSPC)+12.30%

1-Year Return

AYTU+12.14%

S&P 500 (^GSPC)+16.05%

3-Year Return

AYTU+42.59%

S&P 500 (^GSPC)+79.65%

5-Year Return

AYTU-96.11%

S&P 500 (^GSPC)+74.97%

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis

Trailing P/E

-1.1x

Forward P/E

N/A

EV/EBITDA

N/A

FCF YieldCash Flow

N/A

Valuation vs 5-Year History

Multiple Range

Metric

Current

5Y Median

Historical Range

Percentile

P/E

-1.1x

N/A

EV/EBITDA

N/A

2.5x

N/A

Price/FCF

N/A

Current Multiple

5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection

No DCF Model AvailableIntrinsic value modeling is not supported for this equity.

Growth & profitability

Annual revenue & EPS trend

Revenue

$66M+1.8% YoY

Net income

-$14M+14.4% YoY

Free cash flow

-$5M-200.8% YoY

Operating margin

-11.8%-9.4 pts YoY

ROIC (TTM)-33.5%

Avg ROIC 5Y-

ROE (TTM)-58.1%

Piotroski Score3 / 9

Financial Statements →

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History

EPS Beat Rate5/12 (42%)

Revenue Beat Rate9/12 (75%)

Quarter	EPS (Act vs Est)	Revenue (Act vs Est)
Q4 2026Latest Sep 22, 2026	$0.21+172.4% vs -$0.29	$16M+31.2% vs $12M
Q2 2026 May 13, 2026	-$0.53-19.5% vs -$0.44	$12M+3.0% vs $12M
Q1 2026 Feb 3, 2026	-$1.05-303.8% vs -$0.26	$15M+24.9% vs $12M
Q4 2025 Nov 13, 2025	-$0.08-33.3% vs -$0.06	$14M+10.2% vs $13M

Historical baseline: 12 quarters analyzedGAAP / Adjusted

MARKET COVERAGE

Latest News

4 Stories

Accesswire·Sep 16, 2026

Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026

DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2026 full year and fourth quarter, after the market close on Tuesday, September 22, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, September 22, 2026, at 4:30 p.m.

Defense World·Aug 26, 2026

AWM Investment Company Inc. Invests $1.33 Million in Aytu BioPharma Inc. $AYTU

AWM Investment Company Inc. bought a new stake in Aytu BioPharma Inc. (NASDAQ: AYTU) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 619,574 shares of the company's stock, valued at approximately $1,332,000. AWM Investment Company Inc. owned

Zacks Investment Research·Jul 20, 2026

New Strong Sell Stocks for July 20th

ACR, AEM and AYTU have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2026.

Zacks Investment Research·Jul 16, 2026

New Strong Sell Stocks for July 16th

AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026.

Filtered for Aytu BioPharma, Inc.More Headlines

Compare before deciding

Benchmark AYTU against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Aytu BioPharma, Inc. (AYTU)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
AYTUAytu BioPharma, Inc.Current	$2.31	$18.71M	-1.07	1.84%	-20.43%	-58.1%	—
SUPNSupernus Pharmaceuticals, Inc.	$43.29	$2.51B	-63.66	8.63%	-13.23%	-10.42%	—
TPVGTriplePoint Venture Growth BDC Corp.	$4.81	$195.28M	3.94	55.25%	45.97%	10.97%	—
ASRTAssertio Holdings, Inc.	$23.50	$151.86M	-4.96	-5%	-34.94%	-38.72%	—
PRGOPerrigo Company plc	$14.68	$2.03B	-1.43	-2.75%	-41.85%	-55.97%	—
COLLCollegium Pharmaceutical, Inc.	$22.64	$734.3M	13.09	23.62%	5.93%	15.96%	—

Compare AYTU vs Peers

Aytu BioPharma, Inc. (AYTU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs SUPN

Most directly comparable listed peer for AYTU.

Scale Benchmark

vs CVS

Larger-name benchmark to compare AYTU against a more recognizable public peer.

Peer Set

Compare Top 5

vs SUPN, TPVG, ASRT, PRGO

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

AYTU SEC Filings & Documents

Aytu BioPharma, Inc. (AYTU) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 13, 2026·SEC

Material company update

Apr 2, 2026·SEC

Material company update

Feb 3, 2026·SEC

10-K Annual Reports

FY 2025

Sep 23, 2025·SEC

FY 2024

Sep 26, 2024·SEC

FY 2023

Oct 12, 2023·SEC

10-Q Quarterly Reports

FY 2026

May 13, 2026·SEC

FY 2026

Feb 3, 2026·SEC

FY 2025

Nov 13, 2025·SEC

Get notified when AYTU posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

AYTU Frequently Asked Questions

Aytu BioPharma, Inc. (AYTU) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Aytu BioPharma, Inc.'s revenue?

Aytu BioPharma, Inc. (AYTU) reported $56.6M in revenue for fiscal year 2025.

How fast is Aytu BioPharma, Inc. growing?

Aytu BioPharma, Inc. (AYTU) grew revenue by 1.8% over the past year. Growth has been modest.

Is AYTU profitable?

Aytu BioPharma, Inc. (AYTU) reported a net loss of $34.1M for fiscal year 2025.

Dividend & Returns

What is AYTU's return on equity?

Aytu BioPharma, Inc. (AYTU) has a return on equity (ROE) of -58.1%. Negative ROE indicates the company is unprofitable.

What is Aytu BioPharma, Inc.'s free cash flow?

Aytu BioPharma, Inc. (AYTU) generated $1.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in AYTU back in 2007?

Total return calculator · dividends reinvested · 19+ years of data

See returns →

Quarter

EPS (Act vs Est)

Revenue (Act vs Est)

Q4 2026Latest

Sep 22, 2026

$0.21+172.4%

vs -$0.29

$16M+31.2%

vs $12M

Q2 2026

May 13, 2026

-$0.53-19.5%

vs -$0.44

$12M+3.0%

vs $12M

Q1 2026

Feb 3, 2026

-$1.05-303.8%

vs -$0.26

$15M+24.9%

vs $12M

Q4 2025

Nov 13, 2025

-$0.08-33.3%

vs -$0.06

$14M+10.2%

vs $13M

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

AYTUAytu BioPharma, Inc.Current

$2.31

$18.71M

-1.07

1.84%

-20.43%

-58.1%

—

SUPNSupernus Pharmaceuticals, Inc.

$43.29

$2.51B

-63.66

8.63%

-13.23%

-10.42%

—

TPVGTriplePoint Venture Growth BDC Corp.

$4.81

$195.28M

3.94

55.25%

45.97%

10.97%

—

ASRTAssertio Holdings, Inc.

$23.50

$151.86M

-4.96

-5%

-34.94%

-38.72%

—

PRGOPerrigo Company plc

$14.68

$2.03B

-1.43

-2.75%

-41.85%

-55.97%

—

COLLCollegium Pharmaceutical, Inc.

$22.64

$734.3M

13.09

23.62%

5.93%

15.96%

—